Workflow
Lyra Therapeutics(LYRA)
icon
Search documents
Lyra Therapeutics(LYRA) - 2020 Q3 - Quarterly Report
2020-11-10 21:42
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) ...
Lyra Therapeutics(LYRA) - 2020 Q2 - Earnings Call Transcript
2020-08-11 21:59
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Laurence Watts - Managing Director Gilmartin Group Maria Palasis - President and Chief Executive Officer Don Elsey - Chief Financial Officer Corinne Noyes - Senior Vice President of Commercial Strategy and Market Development Conference Call Participants Ashwani Verma - Bank of America Chris Howerton - Jeffries Robert Hazlett - BTIG Operator Welcome to the Lyra Therapeutics Second Quarter 20 ...
Lyra Therapeutics(LYRA) - 2020 Q2 - Quarterly Report
2020-08-05 20:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Stat ...
Lyra Therapeutics(LYRA) - 2020 Q1 - Quarterly Report
2020-05-28 20:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Sta ...